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Abstract
Hepatitis C virus (HCV) is one of the main causes of liver disease and transplantation world-
wide. Current therapy is expensive, presents additional side effects and viral resistance has
been described. Therefore, studies for developing more efficient antivirals against HCV are
needed. Compounds isolated from animal venoms have shown antiviral activity against
some viruses such as Dengue virus, Yellow fever virus and Measles virus. In this study, we
evaluated the effect of the complex crotoxin (CX) and its subunits crotapotin (CP) and phos-
pholipase A2 (PLA2-CB) isolated from the venom of Crotalus durissus terrificus on HCV life
cycle. Huh 7.5 cells were infected with HCVcc JFH-1 strain in the presence or absence of
these toxins and virus was titrated by focus formation units assay or by qPCR. Toxins were
added to the cells at different time points depending on the stage of virus life cycle to be
evaluated. The results showed that treatment with PLA2-CB inhibited HCV entry and replica-
tion but no effect on HCV release was observed. CX reduced virus entry and release but not
replication. By treating cells with CP, an antiviral effect was observed on HCV release, the
only stage inhibited by this compound. Our data demonstrated the multiple antiviral effects
of toxins from animal venoms on HCV life cycle.
Introduction
Hepatitis C is a disease caused by Hepatitis C virus (HCV) infection, essentially characterized
by liver inflammation. Chronic infection may progress to cirrhosis or hepatocellular carci-
noma and represents one of the major causes of liver diseases and transplants [1]. Approxi-
mately 130–150 million people are chronically infected worldwide [2].
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HCV is grouped into the genus Hepacivirus within the family Flaviviridae. Virions are
enveloped and present and a single stranded positive-sense RNA genome surrounded by a
proteic capsid [3]. There is no vaccine for preventing HCV infection and for many years the
interferon-based was the only treatment against HCV infection [4].
Recently, the addition of the direct-acting antiviral agents (DAAs) which target viral pro-
teins such as NS5A and NS3-4A to the standard interferon therapy or the interferon-free regi-
mens increased the sustained virological response (SVR) rates [5,6]. Sofosbuvir and daclatasvir
are two oral DAAs which increase SVR even for difficult-to-treat genotypes, demonstrating
high tolerance for patients. However, DAAs based therapies cost approximately US$84,000 for
12-week treatment, making this regimens inaccessible for many countries [7,8]. Additionally,
studies have demonstrated that specific mutations may confer viral resistance to its treatment
[9]. Therefore, the search for new therapeutics for the treatment of HCV infection is of great
interest and could provide a substantial benefit to the global public health [10].
In this context, compounds extracted from natural sources have shown therapeutic poten-
tial for treating chronic hepatitis C [11–13]. Toxins isolated from animals as the poisonous
snakes have been widely studied with respect to their applications, including antiviral proper-
ties [14–17]. Snake venoms are a mixture of bioactive compounds that possess numerous met-
abolic activities [18]. These compounds previously demonstrated to inhibit the life cycle of a
range of viruses, including the Flaviviridae family. Components of snake venoms have shown
antiviral activity against Dengue virus (DENV), Yellow Fever virus (YFV), Oropouche virus
(OROV), Mayaro virus (MAYV) [16,19], Measles virus (MeV) [17] and Human immunodefi-
ciency virus (HIV) [15,20]. Therefore, toxins isolated from venomous snakes may provide an
alternative approach for the development of new antivirals.
In this study, we investigated the antiviral effects of the complex crotoxin and its subunits
crotapotin and phospolipase A2 isolated from the venom of Crotalus durissus terrificus [19,21]
on HCV life cycle. The data obtained showed that these toxins can inhibit different stages of
the viral replicative cycle.
Material and methods
Toxins
The crude venom from Crotalus durissus terrificus was purchased from the serpentarium "Ani-
mal Toxin Extraction Center" (CETA) duly registered in Ministry of the Environment, nr.
3002678. The extraction was performed by Jairo Marques do Vale (CETA). The venom was
collected from 28 specimens (pool) from Morungaba—SP collection.
Isolation and purification of the crotoxin complex (CX), and its subunits phospholipase A2
(PLA2-CB) and crotapotin (CP) (Fig 1) were carried out at the Laboratory of Toxinology of
the School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (IBAMA
authorization: 1/35/1998/000846-1), under the supervision of Prof Suely Vilela Sampaio, as
previously described in details [19,21].
Lyophilized toxins were dissolved in PBS (Phosphate-Buffered Saline), filtered and stored at
-80˚C. Compounds were diluted in complete medium immediately prior to the experiments.
Cell culture
The human hepatoma cell line Huh-7.5 [22] was grown in Dulbecco’s modified Eagle’s
medium (DMEM; Sigma–Aldrich, USA) supplemented with 100 U/mL penicillin (Gibco Life
Technologies, USA), 100 mg/mL streptomycin (Gibco Life Technologies, USA), 1% non-
essential amino acids (Gibco Life Technologies, USA), 1% HEPES (Gibco Life Technologies,
USA) and 10% fetal bovine serum (FBS; Cultilab, BR) at 37˚C in a humidified 5% CO2
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incubator. The subgenomic replicon (SGR) cell lines harboring genotype 2a SGR-Feo-JFH-1
[23] or genotype 1b SGR BM45-Feo [24] was maintained in DMEM supplemented with
500 μg/mL G418 (Sigma-Aldrich, USA).
Cytotoxicity assay
Cytotoxicity of toxins was measured by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide] (Sigma–Aldrich, USA) method [25]. Huh-7.5 or SGR-harboring cells
were cultured in DMEM medium in a 96-well plate at a density of 5 x 103 per well and incu-
bated at 37˚C in a humidified 5% CO2 incubator overnight. Two fold serial dilutions of toxins
(100 to 1.56 μg/mL) were added to the cell culture. Cells treated with PBS were used as
untreated control. After 48 h incubation at 37˚C, DMEM containing MTT at the final concen-
tration of 1 mg/mL was added to each well, incubated for 1 hour and replaced with 100 μl of
DMSO to solubilize the formazan crystals. Surviving cells were measured by optical density
(OD) at 562 nm, using a spectrophotometer. In order to support the results obtained from
MTT assay, cell viability was also analyzed by using Cell Titer-Blue Luminescent Cell Viability
Assay (Promega) according to the manufacturers’ protocol. The 50% cytotoxic concentration
(CC50) was defined as the concentration required to reduce the cell number by 50% compared
to that for the untreated control. All experiments were performed in triplicates and repeated a
minimum of three times.
Luciferase-based replication assay
Huh-7.5 cells stably harboring the SGR-Feo-JFH-1 or electroporated with SGR BM45-Feo
were seeded into 96-well plates at a density of 5 x 103 per well and toxins at specific concentra-
tions were added. After 48 h, cells were harvested by lysis with Passive Lysis Buffer (Promega,
USA) and HCV RNA replication was quantified by measuring luminescence levels using the
Luciferase Assay System (Promega, USA). The effective concentration of toxins that inhibit
50% (EC50) of replication was calculated using GraphPad Prism software. Cytotoxicity assays
Fig 1. Crystal structure of the complex crotoxin from Crotalus durissus terrificus venom. The basic subunit (PLA2-CB) is
displayed in blue (A). The overall structure of crotoxin complex (B). The three chains of acid subunit (crotapotin) is shown in red [α],
light pink [β] and pink [γ] and (C) (PDB ID: 3R0L).
https://doi.org/10.1371/journal.pone.0187857.g001
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were carried out in parallel to determine the CC50, using a MTT-based system as described
above. The values of CC50 and EC50 were used to calculate the selectivity index (SI = CC50/
EC50).
Combined treatment assay
Huh-7.5 cells stably harboring the SGR-Feo-JFH-1 were seeded into 96-well plates at a density
of 5 x 103 the day before the assay was carried out. Toxin and Sofosbuvir were added sepa-
rately, or combined at sub-EC50 concentrations. After 48h. cells were harvested by lysis with
Passive Lysis Buffer (Promega, USA) and HCV RNA replication was quantified by measuring
luminescence levels using the Luciferase Assay System (Promega, USA), as described in Lucif-
erase-based replication assay.
Virus assays
JFH-1 HCVcc particles [26] were generated as described previously [27]. Huh-7.5 cells were
infected with virus at a multiplicity of infection (MOI) of 0.4 and toxins at 10 μg/mL were
added at different time points, depending on the stage of HCV life cycle to be evaluated (as
described below). To virus titration, HCVcc supernatants were 10-fold serial diluted in
DMEM medium and used to infect Huh-7.5 cells. Cells were fixed with 4% paraformaldehyde
(PFA) 48 h post-infection (hpi), washed with 100 mM Glicine (Applichem, USA) and semi-
permeabilized with 0.1% Triton X-100 (Vetec Labs, BR). Intracellular virus was detected by
indirect immunofluorescence using a sheep anti-NS5A IgG [28] as primary antibody and anti-
sheep IgG, Alexa Fluor 594 conjugated, as secondary antibody. Infectivity was expressed as
focus-forming units per milliliter of supernatant (FFU/mL). All assays were performed in trip-
licates and repeated a minimum of three times.
Antiviral activity against HCV replication
Huh-7.5 cells were seeded the day before the assay was carried out. Toxins were diluted to the
stated final concentrations in DMEM media. Cells were infected with infectious supernatant
for 4 h, washed extensively with PBS to remove non-endocytosed virus particles and toxins
were added. After 48 h intracellular virus was titrated. PBS was used as untreated control and
cyclosporine A (CsA, Sigma-Aldrich) as control of inhibition of replication [29].
Inhibitory effects on entry steps
Infectious supernatant containing JFH-1 HCVcc was used to infect naive Huh-7.5 cells in the
presence of toxins for 4 h at 37˚C. Cells were extensively washed with PBS and replaced with
fresh complete medium.
For virucidal assay, infectious supernatant was prior incubated with toxins for 1 h at 37˚C
and then used to infect naive Huh-7.5 cells. Virus and toxin were incubated with cells for 4 h
at 37˚C. The inoculum was removed; cells were washed three times with PBS to completely
remove virus and toxins, and replaced by fresh media.
For both assays, virus was titrated 48 hpi. PBS and (-)-epigallocatechin gallate (EGCG,
Sigma-Aldrich, USA) [30] were used as controls.
Pre-treatment assay
Huh-7.5 cells were incubated with toxins for 1 hour at 37˚C in a humidified 5% prior to infec-
tion. After incubation, cells were washed extensively and incubated with HCVcc JFH-1 virus
for 4 h. Infectious supernatant was removed, additional washes were performed to completely
Snake toxins inhibit HCV life cycle
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remove non-endocytosed virus and fresh media was added. Virus was titrated 48 hpi as
described above. PBS and EGCG were used as controls.
Toxins activity on viral release
Huh-7.5 cells infected with HCVcc JFH-1 were seed 48 h prior the treatment. Then, fresh
media with toxins at 10 μg/mL was added following a previously described protocol [31]. The
plate was gently agitated 24 h post-treatment to mechanically release particles bound to cells
and the supernatant was collected, filtered, and stored at—80˚C. Intracellular RNA was also
extracted by using TRIzol reagent (Life Technologies, Carlsbad, CA, USA) and stored at—
80˚C. Both procedures followed Nahmias et al. (2008) protocol for HCV secretion analysis.
Extracted RNA was used on cDNA synthesis using High-Capacity cDNA Archieve
(Applied Biosystems, Foster City, CA, USA). HCV expression analysis was performed for
detection of the HCV5’UTR region using TaqMan Universal PCR Master Mix no AmpErase
UNG (Applied Biosystems, Branchburg, NJ, USA). The amplification of the endogenous gene
GAPDH was used to normalize levels of expression. PBS was used as negative control and nar-
ingenin (NR) at 400 μM was used as positive control of HCV secretion inhibition.
dsRNA intercalation assay
A dsRNA intercalation assay was performed based on the protocol described by [32]. HCV
JFH-1 3’ untranslated region (UTR) (accession no. AB047639) was amplified by a PCR reac-
tion using specific primers flanked by T7 promoter region (forward: 5´TAATACGACTCACTA
TAGGGGGCACACACTAGGTACA3´; reverse: 5´TAATACGACTCACTATAGGGACATGATCTG
CAGAGAG3´; T7 sequences are underlined). The PCR product of 273 bp was purified using
the Zymoclean Gel DNA recovery Kit (Zymo Research) and used as template for in vitro tran-
scription with the T7 RiboMAX™ Express Large Scale RNA Production System kit (Promega).
The synthetized dsRNAs were treated with RNase A for 2 h in a 0.3 M NaCl solution and con-
firmed by RNA denaturation agarose gel (1%) analysis (RNase A does not cleave dsRNA in 0.3
M NaCl solution). To investigate the dsRNA intercalation properties of the compounds, 15
mM dsRNA were incubated with each toxin at 10 μg/mL for 45 m and submitted to agarose
gel analysis. PBS and Doxorubicin (DOX) at 400 μg/mL [32] were used as negative and positive
control, respectively.
CD-81 receptors assay
Huh-7.5 cells were seeded to 96-well plate the day before the assay and incubated at 37˚C in a
humidified 5% CO2 incubator. The media was removed, cells were incubated for 30 minutes
with CD81/TAPA1 antibody (Thermo Scientific) and the respective toxin at 10 μg/ml in PBS
containing 1% BSA (Bovine Serum Albumin—Sigma-Aldrich). After treatment, cells were
washed with PBS and incubated with secondary antibody Alexa Fluor 594 (Thermo Fisher).
After this, cells were washed with PBS, fixed with 4% paraformadehyde (vol/vol), stained for
nuclei with 4 =, 6-diamidino-2-phe-nylindole (DAPI) and analyzed on Fluorescence micros-
copy ZEN lite 2012.
Western blot analysis
Cells were lysed in CelLytic™ lysis buffer (Sigma-Aldrich) added of protease inhibitors (Sigma-
Aldrich). Ten micrograms of protein were resolved by SDS/PAGE and transferred to a PVDF
membrane. Membranes were blocked in 10% (w/v) dried skimmed milk powder in Tris-buff-
ered saline with 0.1% Tween-20 (TBS-T). Membranes were probed with anti-NS5A IgG
Snake toxins inhibit HCV life cycle
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(Macdonald et al., 2003) or mouse anti-GAPDH IgG (AbCam) in 5% (w/v) dried skimmed
milk in TBS-T. The antibodies were detected with the secondary horseradish peroxidase-con-
jugated antibody and in-house enhanced chemiluminescent reagent.
Immunofluorescence assay
Cells grown on glass coverslips were fixed for 10 min with 4% (vol/vol) paraformaldehyde in
PBS at room temperature, washed with 100 mM Glicine (Applichem, USA) and semi-permea-
bilized with 0.1% Triton X-100 (Vetec Labs, BR). Cells were washed with PBS and blocked in
PBS–1% bovine serum albumin (BSA) for 30 min prior to incubation with primary antibodies
for 1 h in PBS–1% BSA with polyclonal sheep anti-NS5A IgG [27] as primary antibody and
anti-sheep IgG, Alexa Fluor 594 conjugated, as secondary antibody. Cells were washed,
mounted onto microscope slides and labelled for nuclei and lipid droplets (LDs) labels with
DAPi and BODYPI 493/503, respectively.
Statistical analysis
Differences between means of readings were compared using analysis of variance (one-way or
two-way ANOVA) or Student t test using GraphPad Prism 5.0 software (GraphPad Software).
P values of less than 0.001 (indicated by asterisks) were considered to be statistically
significant.
Results
Inhibitory effect of toxins on HCV replication
To evaluate the potential effect of the CX, CP and PLA2-CB toxins on HCV replication, we
first used a subgenomic replicon system. Huh-7.5 cell line stably expressing SGR-FEO-JFH-1
(Huh-7.5-SGR-FEO-JFH-1) were treated with two fold serial dilutions (100–1.56 μg/mL) of
each toxin for 48 h to assess the effect of these compounds on both HCV replication and cell
viability (Fig 2). The results showed that PLA2-CB significantly (p< 0.001) inhibited HCV rep-
lication at non-cytotoxic concentrations (Fig 2A); while CX did not demonstrate any effect on
SGR replication (Fig 2B). In contrast, cells treated with 100, 50 and 25 μg/mL of CP signifi-
cantly (p< 0.001) increased HCV replication rates (Fig 2C). Treatment of cells with PLA2-CB
decreased HCV replication in a dose-dependent manner with EC50 of 6.08 μg/mL, CC50 of
17.84 μg/mL and a SI of 2.93 (Fig 2D). As shown in Fig 2E, expression of HCV NS5A protein
was also gradually reduced in the presence of increasing non-cytotoxic doses of PLA2-CB (20–
4 μg/mL). To support MTT data, cell viability was also analyzed by using Cell Titer-Blue Lumi-
nescent Cell Viability Assay (Promega) (S1 Fig). No significant differences were observed in
CX and CP cell viability. However, a significant difference was observed for PLA2-CB at 100,
50 and 25 μg/mL concentrations, showing an increase in viability when compared to the MTT
assay.
The antiviral activity of PLA2-CB was also evaluated against the replication of HCV geno-
type 1b by using a subgenomic system (genotype 1b SGR BM45-Feo). Results corroborated the
data observed for genotype 2a (Fig 3A and 3B), no significant differences were observed
between the two systems. Subsequent assays were performed with toxins at 10 μg/mL final
concentration (favorable ratio of cytotoxicity to antiviral potency).
We next analyzed the effects of the toxins CX, CP and PLA2-CB on genome replication in
the context of full length virus. Huh-7.5 cells were infected with JFH-1 HCVcc at MOI 0.4 for
4 h, washed to remove non-endocytosed virus particle and added of toxins. Replication levels
were assessed by the focus formation units assay 48 h post-infection. Consistent with the SGR
Snake toxins inhibit HCV life cycle
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data, PLA2-CB effectively blocked (p< 0.001) virus replication (Fig 4A). No significant differ-
ences on virus replication rates were observed by treating infected cells with CX or CP (p<
0.001). These results suggest that only the isolated form of PLA2-CB is able to reduce HCV rep-
lication, whereas it has no effect on replication when associated with CP to form the CX
complex.
In an attempt to elucidate the mechanism in which PLA2-CB inhibits HCV replication, we
performed a standard methodology to analyze the potential of the toxins to intercalate into
dsRNA. As shown in Fig 4B, treatment with PLA2-CB reduced 86% of dsRNA stained by
ethidium bromide (Fig 4B). CX showed an intermediate reduction (58%); while CP demon-
strated no effect on the dsRNA. The positive control doxorubicin decreased 77% of dsRNA
stained and demonstrated to be less efficient than PLA2-CB (Fig 4B). These results suggest that
the inhibition of replication by PLA2-CB may be due to its dsRNA intercalation properties.
We also evaluated the effect of PLA2-CB in the presence or absence of the DAA Sofosbuvir
[33] at sub-EC50 concentrations. Huh-7.5 cells stably harboring the SGR-Feo-JFH-1 were
seeded into 96-well plates and treated with the respective compound after 48 h the luciferase
levels were measured. PLA2-CB and Sofosbuvir were diluted separately in DMEM, to be incu-
bated at the final concentrations 3,8 μg/mL and 150 ɳM, respectively, in monotherapy or in
Fig 2. Inhibitory activity of the toxins on HCV replication. Huh-7.5 cell line stably expressing SGR-luc-JFH-1 were treated with PLA2-CB (A), CX (B),
CP (C) at specific concentrations for 48 h. The effective concentration of inhibition (EC50), the cytotoxic concentration of 50% (CC50), and the selectivity
index (SI = CC50/EC50) were calculated (D). Expression of HCV NS5A protein was measured 48 h post-treatment using western blotting assays (E). Mean
values of three independent experiments each measured in triplicate including the standard deviation are shown. P < 0.001 was considered significant (*).
https://doi.org/10.1371/journal.pone.0187857.g002
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combined treatment. At the sub-EC50 concentrations, PLA2-CB or Sofosbuvir inhibited up to
22.7% and 39,7% of HCV replication, respectively, and combined therapy significantly
increased the replication blockage up to 55.8% (p< 0.001) (Fig 5A) at non-cytotoxic concen-
trations (Fig 5B).
Crotoxin complex and its subunit PLA2-CB inhibited HCV entry
The effect of the toxins CX, CP and PLA2-CB on different stages of HCV entry was investi-
gated. First, Huh-7.5 cells were infected with JFH-1 HCVcc and toxins were immediately
added. Cells were incubated with virus plus toxin inoculums for 4 h, washed to completely
remove the inoculum and replaced with fresh medium for 48 h. Intracellular virus were
titrated by using focus formation units assay. The results demonstrated that CX and PLA2-CB
were able to block 85% and 97.3% of HCV entry, respectively. Contradictory, CP showed no
inhibitory effect on viral entry (Fig 6A). It suggests that the inhibition of HCV entry might be
related to the catalytic action of PLA2-CB. The activity observed in CX treatment may be due
to the PLA2-CB presence into the CX complex.
To characterize the antiviral effect of CX and PLA2-CB on virus entry, we next assessed the
impact of these toxins on the HCV viral particle by performing a virucidal assay. JFH-1
HCVcc supernatant was incubated with each toxin in cell-free conditions for 1 h prior to the
cells infection. The inoculum was then used to infect Huh-7.5 cells for 4 h. Cells were washed
with PBS to remove the inoculum and replaced with fresh media. CX and PLA2-CB demon-
strated a significant virucidal activity, blocking 75.5% and 93% of virus entry, respectively
Fig 3. Effect of toxins on genotype 1b. Huh-7.5 cells were electroporated with 2 μg of RNA SGR-Feo-BM-45 genotype 1b and seeded into 96-well plate.
After 24 h, cells were treated with PLA2-CB, CX or CP at 12.5 μg/mL and maintained for 48 h. HCV replication was quantified by measuring luminescence
levels (A) and cell viability absorbance (B). P < 0.001 was considered significant (*).
https://doi.org/10.1371/journal.pone.0187857.g003
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(p<0.001) (Fig 6B). CP also demonstrated no virucidal activity on HCV virus. This result
could suggest that the antiviral effect of CX and PLA2-CB observed was due to a direct action
of these toxins on the virus particle structure.
We further investigated whether the blockage of viral entry by the toxins is influenced by its
activity on the host cells. Huh-7.5 cells were previously treated with toxins for 1 h and then
infected with JFH-1 HCVcc virus for 4 h. Intracellular virus was titrated 48 hpi. The analysis
showed that treatment with PLA2-CB prior to infection significantly inhibited 73.5% of HCV
infectivity (Fig 6C). Therefore, PLA2-CB may also act somehow on the host cells to decrease
infectivity. In contrast, previous treatment on cells with CX and CP had not effect on HCV
infectivity (Fig 5C), suggesting that PLA2-CB probably lacks the antiviral activity when associ-
ated with CP to form CX.
We also analyzed whether the antiviral activity of PLA2-CB or CX is due to an interaction
between these toxins and CD-81 cell receptors. However, our data suggested that the antiviral
activity of toxins is not by binding to CD-81 cell receptors (Fig 7).
HCV release is inhibited by crotapotin and crotoxin but not by PLA2-CB
Finally, we investigated the effect of toxins on HCV release. HCVcc JFH-1 infected cells were
treated with each toxin at 10 μg/mL for 24 h. Supernatants were collected and cells were
Fig 4. Effect of toxins on HCV replication. Huh7.5 cells were infected with JFH-1 HCVcc for 4 h, Then cells were washed extensively to remove virus
and treated with toxins. Replication levels were assessed by performing the focus formation units assay 48 h post-infection. PBS was used as negative
control and CsA as positive control for replication inhibition. Mean values of three independent experiments each measured in triplicate including the
standard deviation are shown. P < 0.001 was considered significant (A). In an attempt to determine de antiviral mechanism of action of these toxins,
synthesized dsRNA was incubated with each toxin for 45 min and submitted to electrophoresis in 1% agarose gel. PBS was used as negative control and
Doxorubicin (DOX) was used as intercalating positive control (B).
https://doi.org/10.1371/journal.pone.0187857.g004
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harvested, and viral RNA was quantified by qPCR. Intra and extracellular virus tires were
analyzed in order to evaluate the amounts of virus produced (intracellular) and released (extra-
cellular). Treatment with PLA2-CB showed no significant difference between intra and extra-
cellular virus demonstrating no effect on virus release—all virus produced is released (PLA2-
CB affects earlier steps of HCV life cycle, then lower amounts of virus is produced but is also
released) (Fig 8). The reduction of both intra and extracellular viral RNA observed for PLA2-
CB compared to the PBS control was the consequence of its effect on HCV replication. In con-
trast, the treatment with CX and CP demonstrated significant difference on levels of intra and
extracellular HCV RNA and therefore, on virus release (virus is produced in earlier steps but
not released from cells). The results showed that CX and CP reduced 50 and 78% of HCV
release, respectively (Fig 8). Interestingly, the interpretation of these results may suggest that
the inhibitory action of CX on HCV release, could be related to the presence of subunit CP in
this complex, and its effect it is not influenced by the interaction of subunits to form CX
complex.
PLA2-CB and crotapotin affect lipid metabolism in Huh-7.5 cells
Given the described links between the HCV life cycle and the host lipid metabolism, we evalu-
ated whether the treatment with toxins disturbed the lipid metabolism of Huh-7.5 cells stably
harboring the SGR-Feo-JFH-1. The treatment with PLA2-CB or CP at 10 μg/mL decreased
of LDs levels compared to untreated control, but no effect was observed for CX (Fig 9). As
expected, PLA2-CB also reduced NS5A protein levels due to the antiviral activity on HCV rep-
lication as shown in Figs 2, 3 and 4. Therefore, PLA2-CB reduced both viral protein LDs levels.
Interesting, CP also interferes in lipid metabolism but did not reduced HCV replication levels
levels, in accordance to the data presented on Figs 2, 3 and 4. However, since HCV assembly
occurs in close proximity to lipid droplets [34,35], the reduction of LDs by CP could be related
to its antiviral effect on HCV release (Fig 8).
Fig 5. Sofosbuvir and PLA2-CB combined treatment. Huh-7.5 cells stably harboring the SGR-Feo-JFH-1 were seeded into 96-well plates and treated
with PLA2-CB, Sofosbuvir or the combination PLA2-CB and Sofosbuvir for 48 h. After the treatment replication level (A) and cell viability (B) were
measured. P < 0.001 was considered significant (*).
https://doi.org/10.1371/journal.pone.0187857.g005
Snake toxins inhibit HCV life cycle
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Discussion
The current available therapy for Hepatitis C is not effective for all treated patients, is limited
by side effects and is expensive. Therefore, there is an evident need to develop new therapeu-
tic approaches that result in optimal response rates, milder side effects and lower cost of
production.
Several studies have described compounds isolated from snake venoms with anti-bacterial,
anti-inflammatory, anticancer and antiviral activity [17,36]. Since the discovery of captopril, a
potent anti-hypertensive drug based on snake venom protein [37], many toxins are being
investigated due to their therapeutic potential. Toxins isolated from Crotalus durissus terrificus
were previously screened for their activity against other viruses of Flaviviridae family and dem-
onstrated to be effective on blocking the early steps of the life cycle of these viruses [19]. CX
was initially described with neurotoxic and myotoxic activity however over the years new
activities like anti-inflammatory, antimicrobial and antitumor have been described for this
complex [38,39].
In this study, we investigated the antiviral activities of the heterodimeric complex CX, and
its subunits CP and PLA2-CB, isolated from Crotalus durissus terrificus venom against HCV
Fig 6. Effect of the toxins on HCV infectivity. Infectious supernatant and toxins were added in different times to the cells and intracellular virus was
titrated 48 h post-infection by analyzing focus-forming units per milliliters (Ffu/mL). For entry assay, Huh-7.5 cells were infected with JFH-1 HCVcc and
toxins were immediately added. After 4 h, the supernatant was replaced by fresh medium after repeated washes with PBS to remove completely the
inoculum (A). For virucidal assay, JFH-1 HCVcc particles were incubated with toxins for 1 h prior to the infection. After that, the inoculum was used to infect
naïve Huh-7.5 cells for 4 h. Cells were extensively washed and medium was added (B). In the pre-treatment assay, cells were previously treated with
toxins for 1 h, washed to completely remove toxins and infected with JFH-1 virus for 4 h. Cells were then washed to virus removal and replaced with fresh
media for up to 48 h post-infection (C). PBS was used as negative control and EGCG as control of entry blockage. Mean values of three independent
experiments each measured in triplicate including the standard deviation are shown. P < 0.001 was considered significant.
https://doi.org/10.1371/journal.pone.0187857.g006
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infection in vitro. We were able to demonstrate the multiple antiviral effects of these toxins
which inhibited different stages of the HCV life cycle.
Crotoxin is a noncovalent association formed by two subunits, acidic subunit CP (9.5 kDa)
formed by three polypeptide chains (α, β, and γ) cross-linked by seven disulfide bonds and
basic subunit PLA2-CB (14.5 kDa). Subunit B is a phospholipase formed by a single chain of
122 amino acid residues cross-linked by seven disulfide bonds [40,41].
Our data showed that PLA2-CB blocked viral entry by both the action on the virus particle
and somehow on the host cells. It is consistent with findings of a previous study which demon-
strated that the PLA2-CB inhibits the early stages of replication cycle of two members of the
Flaviviridae family, DENV and YFV [19]. The authors showed that PLA2-CB reduced virus
infection by acting on the host cells and/or on the viral particles. Additionally, Rojas and col-
laborators demonstrated that the incubation of quercetin with HCVcc in a free-cell condition
prior to the infection of cells significantly reduced HCV infectivity. By their results, the authors
suggested that quercetin acts directly on HCV, modifying the integrity of viral particles [42].
Therefore, our analyses are in agreement with previous data and could suggest that the antivi-
ral effect of CX and PLA2-CB observed was due to a direct action of these toxins on the virus
particle structure. However, we acknowledge that interpretation of these experiments is
challenging and we therefore cannot rule out the possibility that these compounds possess an
independent effect on the host cell components of the receptor complex or interacts with com-
ponents which modulate viral entry. We investigated whether the toxins could abrogate virus
entry by interacting with CD-81 cell receptor, an important factor for HCV infection [43,44].
Our results suggest that the antiviral activity of toxins CX and PLA2-CB on HCV entry is not
by blocking CD-81 cell receptors.
PLA2-CB is a phospholipase which belongs to the group II of secreted enzymes that hydro-
lyze glycerophospholipids at the sn-2 position, producing lysophospholipids and fatty acids
[45]. They represent a versatile class of enzymes which play a key role in various biological
Fig 7. Effect of toxins on CD81 cell receptors. Huh-7.5 cells were incubated with CD81/TAPA1 antibody
and 10 μg/ml of CX, PLA2-CB or PBS. Then cells were washed and incubated with secondary antibody Alexa
Fluor 594. Cells were fixed with 4% paraformaldehyde and labelled for nuclei with DAPI and analyzed on
Fluorescence microscopy ZEN lite 2012.
https://doi.org/10.1371/journal.pone.0187857.g007
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activities, such as lipid digestion, host defense and homeostasis of cellular membranes [45,46].
Once lipids are considered an essential part and associated with different steps in HCV life
cycle [47,48], we evaluated the effect of the toxins on LDs. The results demonstrated that
PLA2-CB was able to decrease the amount of LDs in Huh-7.5 cells combined to the reduction
of NS5A protein levels and blockage of HCV replication. Previous studies also showed that
alterations in LDs are essential to HCV replication [49], and LDs also seem to be extremely
associated to virus replication complex [3,50].
Rojas et. al. [42] also showed that genes involved in lipid synthesis and uptake (Low-density
lipoprotein receptor (LDLr), fatty acid synthesis (FASN), acetyl-CoA carboxylase (ACC), and
transcription factor binding of sterol regulatory elements 1 (SREBP1c) significantly increased.
The expression of the microsomal enzyme diacylglycerol acyltransferase (DGAT), related to
the synthesis of triglycerides and interaction with the core protein for the formation of infec-
tious particles, also showed a significant increase. The increase of DGAT, ACC, LDLr e
SREBP1c, LDLr and SREBP1c expression were completely inhibited by treatment with querce-
tin at 50 uM. The effect of quercetin on the morphology of lipid vesicles was also evaluated,
and a morphometric analysis showed a reduction in the radius, area and volume of lipid drop-
lets [42].
Fig 8. Antiviral activity of toxins on HCV release. Huh-7.5 cells previously infected with JFH-1 virus was plated 48 h prior treatment. The toxins
were added at 10 μg/mL and incubated for 24 h. Supernatant was collected and cells were harvested, and intra and extracellular RNA were
quantified by qPCR. PBS was used as negative control and naringenin (NR) at 400 μM was used as positive control of HCV secretion. Mean
values of three independent experiments each measured in triplicate including the standard deviation are shown. P < 0.001 was considered
significant.
https://doi.org/10.1371/journal.pone.0187857.g008
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Nordihydroguaiaretic acid (NDGA) derived from the species Larrea tridentata inhibited
40% HCV virus replication in 48 hours of treatment when compared to untreated controls. In
addition, NDGA altered lipid metabolism by preventing activation of the SREBP1c gene, LDLr
and FASN target receptors in Huh-7 infected with HCV. The authors also observed that
NDGA treatment induced lipid vesicle rearrangement, decreasing in number and increasing
size. When Huh-7 cells were stimulated with oleic acid and infected with HCV, treatment with
NDGA reduced the number and size of lipid vesicles, this can be explained by vesicle fusion or
secretion of pre-synthesized vesicles [51].
In view of this we suppose that the PLA, CX and CP compounds are inhibiting the expres-
sion of genes responsible for lipid metabolism (DGAT, ACC, LDLr and SREBP1c), which
makes it difficult to assemble the viral particles and thus inhibit replication.
More recently, the effect of PLA2-CB against DENV was associated to its catalytic activity,
inactivating virus particle probably by cleavage of glycerophospholipid of the virus envelope
[52]. These results were also described for other enveloped virus such as Rocio virus,Oropouche
virus, Mayaro virus [16] and Human Immunodeficiency Virus (HIV) [15]. Since HCV is an
enveloped virus [53] and viral particles are also associated with lipoproteins [54], it is plausible
to suggest that the virucidal effect observed in our analysis could be due to the phospholipase
activity attributed to PLA2-CB, however, more studies are necessary to confirm this possibility.
Our results demonstrated that PLA2-CB reduced HCV replication in either subgenomic
reporters SGR-Feo-JFH1 (genotype 2a) or SGR-BM45-Feo (genotype 1b), and also by using
the full-length JFH1 systems. When the inhibitory effects were further investigated, we found
that PLA2-CB strongly intercalated into dsRNA, suggesting a possible mechanism of action in
which PLA2-CB inhibits HCV replication. The association of PLA2-CB with CP decreased the
Fig 9. Effect of toxins on lipids droplets. Huh-7.5 cell line stably expressing SGR-luc-JFH-1 were treated
with 10 μg/mL of CX, CP or PLA2-CB at 37˚ for 48 hours. Cell were fixed and nuclei, Lipid droplets (LDs) and
viral protein NS5A were labelled with DAPi (blue), BODYPI 493/503 (green) and antibodies against NS5A
(red), respectively. PBS was used as untreated control. Scale bars, 200 nm.
https://doi.org/10.1371/journal.pone.0187857.g009
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intercalation property, consistent with the results observed for CX and CP. This result also
could explain the discrete but not significant reduction of full length virus replication by CX
when compared to CP treatment. We believe that either the use of two different systems could
explain the differences between the results or that the effects of CX in the dsRNA is not strong
enough to reduce replication levels, since the dsRNA is produced. The capacity of intercalate
into dsRNA was also previously described for other natural compounds as amidinoanthracy-
clines [32] and acridones [55] against HCV. PLA2-CB also showed a slight increase in replica-
tion blockade when combined with Sofosbuvir. This finding added to the action of the PLA2-
CB in other steps could provide complementary mechanisms of action to HCV inhibition.
[56]Despite CX did not significantly inhibit HCV replication, this complex was effective in
blocking the HCV entry and release stages. The observed data suggests that the effect on HCV
entry is mainly due to its virucidal activity. CX is characterized as a heterodimeric protein
complex consisting of two subunits, an acidic component (CP) and a basic subunit (PLA2-CB)
[21,57–59]. Therefore, the virucidal effect of CX is probably due to the presence of PLA2-CB in
this complex. Altogether, our data shows a stronger virucidal effect when cells are treated with
the isolated form of PLA2-CB, and a significant but reduced effect when it is in the complex
form. This pattern of activity was similarly found concerning other biological activities of the
CX. According to Sampaio et al., the enzymatic activity related to CX was also associated with
the presence of the subunit PLA2-CB [39].
Interestingly, our data demonstrated that CP possesses inhibitory effect on HCV release
and interferes with lipid metabolism, but did not reduced NS5A protein levels. CP was initially
described with no catalytical or cytotoxic activities and acts mainly preventing PLA2-CB to
perform unspecific interactions [60–62]. Miyanari, et al. demonstrated that some steps of virus
assembly occurs around LDs [34]. Additionally, the flavonoid Naringenin demonstrated to
inhibit the secretion of HCV particles, without affecting intracellular levels of viral RNA or
protein [63]. This finding corroborated with our data, therefore we hypothesize that the antivi-
ral effect of CP on HCV release could be due to the decrease of LDs in treated Huh-7.5 cells.
Conclusion
In summary, we demonstrated that toxins isolated from Crotalus durissus terrificus can inhibit
different stages of HCV life cycle as entry, replication and release. The mechanisms of antiviral
action were: (a) block HCV entry by the direct action of PLA2-CB on the viral particle and/or
interference on the host cells; (b) reduce replication possible by intercalating to the intermedi-
ate dsRNA formed during the replication process; (c) disrupt replication or release by decreas-
ing levels of LDs and interferes with host lipid metabolism. These results may be useful for the
development of future therapies and for a better understand of how these toxins act inhibiting
virus machinery.
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